TY - JOUR
T1 - Assessing the performance of the Birmingham vasculitis activity score at diagnosis for Children with antineutrophil cytoplasmic antibody-associated vasculitis in a registry for childhood vasculitis (ARChiVe)
AU - Morishita, Kimberly
AU - Li, Suzanne C.
AU - Muscal, Eyal
AU - Spalding, Steven
AU - Guzman, Jaime
AU - Uribe, America
AU - Abramson, Leslie
AU - Baszis, Kevin
AU - Benseler, Susanne
AU - Bowyer, Suzanne
AU - Campillo, Sarah
AU - Chira, Peter
AU - Hersh, Aimee O.
AU - Higgins, Gloria
AU - Eberhard, Anne
AU - Ede, Kaleo
AU - Imundo, Lisa
AU - Jung, Lawrence
AU - Kim, Susan
AU - Kingsbury, Daniel J.
AU - Klein-Gitelman, Marisa
AU - Lawson, Erica F.
AU - Lovell, Daniel J.
AU - Mason, Thomas
AU - McCurdy, Deborah
AU - Nanda, Kabita
AU - Nassi, Lorien
AU - O'Neil, Kathleen M.
AU - Rabinovich, Egla
AU - Ramsey, Suzanne E.
AU - Reiff, Andreas
AU - Rosenkranz, Margalit
AU - Schikler, Kenneth
AU - Stevens, Anne
AU - Wahezi, Dawn
AU - Cabral, David A.
PY - 2012/5
Y1 - 2012/5
N2 - Objective: There are no validated tools for measuring disease activity in pediatric vasculitis. The Birmingham Vasculitis Activity Score (BVAS) is a valid disease activity tool in adult vasculitis. Version 3 (BVAS v.3) correlates well with physician's global assessment (PGA), treatment decision, and C-reactive protein in adults. The utility of BVAS v.3 in pediatric vasculitis is not known. We assessed the association of BVAS v.3 scores with PGA, treatment decision, and erythrocyte sedimentation rate (ESR) at diagnosis in pediatric antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Methods: Children with AAV diagnosed between 2004 and 2010 at all ARChiVe centers were eligible. BVAS v.3 scores were calculated with a standardized online tool (www.vasculitis.org). Spearman's rank correlation coefficient (rs) was used to test the strength of association between BVAS v.3 and PGA, treatment decision, and ESR. Results: A total of 152 patients were included. The physician diagnosis of these patients was predominantly granulomatosis with polyangiitis (n = 99). The median BVAS v.3 score was 18.0 (range 0-40). The BVAS v.3 correlations were rs = 0.379 (95% CI 0.233 to 0.509) with PGA, rs = 0.521 (95% CI 0.393 to 0.629) with treatment decision, and rs = 0.403 (95% CI 0.253 to 0.533) with ESR. Conclusion: Applied to children with AAV, BVAS v.3 had a weak correlation with PGA and moderate correlation with both ESR and treatment decision. Prospective evaluation of BVAS v.3 and/or pediatric-specific modifications to BVAS v.3 may be required before it can be formalized as a disease activity assessment tool in pediatric AAV.
AB - Objective: There are no validated tools for measuring disease activity in pediatric vasculitis. The Birmingham Vasculitis Activity Score (BVAS) is a valid disease activity tool in adult vasculitis. Version 3 (BVAS v.3) correlates well with physician's global assessment (PGA), treatment decision, and C-reactive protein in adults. The utility of BVAS v.3 in pediatric vasculitis is not known. We assessed the association of BVAS v.3 scores with PGA, treatment decision, and erythrocyte sedimentation rate (ESR) at diagnosis in pediatric antineutrophil cytoplasmic antibody-associated vasculitis (AAV). Methods: Children with AAV diagnosed between 2004 and 2010 at all ARChiVe centers were eligible. BVAS v.3 scores were calculated with a standardized online tool (www.vasculitis.org). Spearman's rank correlation coefficient (rs) was used to test the strength of association between BVAS v.3 and PGA, treatment decision, and ESR. Results: A total of 152 patients were included. The physician diagnosis of these patients was predominantly granulomatosis with polyangiitis (n = 99). The median BVAS v.3 score was 18.0 (range 0-40). The BVAS v.3 correlations were rs = 0.379 (95% CI 0.233 to 0.509) with PGA, rs = 0.521 (95% CI 0.393 to 0.629) with treatment decision, and rs = 0.403 (95% CI 0.253 to 0.533) with ESR. Conclusion: Applied to children with AAV, BVAS v.3 had a weak correlation with PGA and moderate correlation with both ESR and treatment decision. Prospective evaluation of BVAS v.3 and/or pediatric-specific modifications to BVAS v.3 may be required before it can be formalized as a disease activity assessment tool in pediatric AAV.
KW - Anca
KW - Antineutrophil cytoplasmic antibodies
KW - Vasculitis
KW - Wegener granulomatosis
UR - http://www.scopus.com/inward/record.url?scp=84860781239&partnerID=8YFLogxK
U2 - 10.3899/jrheum.111030
DO - 10.3899/jrheum.111030
M3 - Article
C2 - 22337238
AN - SCOPUS:84860781239
SN - 0315-162X
VL - 39
SP - 1088
EP - 1094
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 5
ER -